ContractWarrant Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
ADAPTIVE BIOTECHNOLOGIES CORPORATION INDEMNIFICATION AGREEMENTIndemnification Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • Washington
This Indemnification Agreement (the “Agreement”) is entered into on , 20 , between Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), and the undersigned officer and/or director of the Company (“Indemnitee”), for good and valuable consideration as set forth below.
— 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.comEmployment Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances)
This letter agreement (this “Agreement”) confirms the terms of your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”).
— 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.comExecutive Severance Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • Washington
This letter agreement (this “Agreement”) confirms the terms of your severance rights in connection with your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), and supplements that certain letter agreement regarding your employment with the Company dated on or about May 1, 2019 (the “Employment Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Employment Agreement.
— 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.comExecutive Severance Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • Washington
This letter agreement (this “Agreement”) confirms the terms of your severance rights in connection with your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), and supplements that certain letter agreement regarding your employment with the Company dated on or about May 1, 2019 (the “Employment Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Employment Agreement.
— 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.comExecutive Severance Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • California
This letter agreement (this “Agreement”) confirms the terms of your severance rights in connection with your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), and supplements that certain letter agreement regarding your employment with the Company dated on or about the date hereof (the “Employment Offer”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Employment Offer.
ADAPTIVE BIOTECHNOLOGIES CORPORATION SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT May 30, 2019Investors’ Rights Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • Washington
THIS SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of May 30, 2019, by and between (i) Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), (ii) each of the investors listed on Schedule A hereto, each of whom is referred to in this Agreement as an “Investor,” and (iii) solely for purposes of Sections 5 and 6 hereof, each of Chad Robins and Harlan Robins and their permitted transferees (the “Key Holders”).
STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • New York
May 8, 2019 Viking Global Equities II LP Viking Global Equities Master Ltd. Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Long Fund Master Ltd. Greenwich, CT 06830 Attention: Katerina Novak Email: legalnotices@vikingglobal.com...Standstill and Support Obligations • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances)
Reference is made to that certain letter agreement regarding standstill and support obligations by and among Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd. and Viking Long Fund Master Ltd. (the “Viking Purchasers”) and Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), dated as of December 11, 2017 (the “Original Letter”), which the Viking Purchasers and the Company entered into in connection with their execution of that certain Series F-1 Preferred Stock Agreement dated as of December 11, 2017 (the “Series F-1 Purchase Agreement”).
— 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.comRestated Non-Employee Director Change in Control Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances)
On behalf of Adaptive Biotechnologies Corporation (the “Company”), I am pleased to offer you the following protections in case of a Change in Control (as defined in the Company’s 2009 Equity Incentive Plan, as amended, the “Plan”). In the event of a Change in Control, and provided you are then providing Service (as defined in the Plan), all stock options or other equity granted to you under the Plan, the Company’s 2019 Equity Incentive Plan and/or other equity incentive plans or programs established by the Company, which are unvested as of the date of such Change in Control shall become immediately vested in full immediately prior to the consummation of the Change in Control.
